← Videos

    Interviews

    The Utility of Psychedelics

    Sam Harris, Andrew Huberman·Huberman Lab Clips·20 min·January 6, 2023

    Summary

    Neuroscientist and meditation teacher Sam Harris joins Andrew Huberman to explain why he considers psychedelics useful: not as an end in themselves, but as a doorway into taking first-person experience seriously. Drawing on a clinical MDMA trial and decades of meditation practice, he distinguishes MDMA from classic, perception-altering psychedelics like LSD and psilocybin. His central point is that the value of these experiences lies less in the altered state itself than in what carries over into ordinary consciousness afterward.

    Caveats and who should avoid these substances

    Harris leads with the conditions he says make psychedelic use responsible: safety, legality, age and context appropriateness, and ideally clinical guidance. Anyone with a personal or family history suggestive of schizophrenia or bipolar disorder is, in his words, "almost certainly" not a good candidate; trials at Johns Hopkins, he notes, screen out participants with first-degree relatives who have these conditions.

    MDMA, and a gateway into meditation

    He pushes back on the single term "psychedelics," since it groups pharmacologically different substances. MDMA, he says, is an amphetamine derivative, sometimes called an entactogen: serotonergic, but without the perceptual distortion of LSD or psilocybin. He took part in a clinical trial of three MDMA doses, near the MAPS research dose (about 125 milligrams with an optional 75 milligram booster), and says it produced lasting, valuable learning. An MDMA experience around age 18 convinced him, a self-described hard-headed skeptic, that exploring the mind firsthand was worth pursuing: he recalls a failed attempt to guide Richard Dawkins through meditation on his podcast, for lack of any prior interest pulling Dawkins's attention inward, unlike a sufficient psychedelic dose, where he says something happens almost every time.

    What fades, and the trap of chasing it

    Under appropriate set and setting, Harris says these experiences often reveal states like unconditional love or a felt oneness with nature, though the memory fades quickly, "like trying to remember a dream," and bad trips remain possible on LSD or psilocybin. He warns against chasing repeated peak experiences, calling that pursuit inherently frustrating since any altered state is, by definition, impermanent.

    The deeper insight, and a return after 25 years

    The more durable insight, in Harris's view, is what contemplative traditions like Buddhism point to, apart from their supernatural elements: recognizing the illusion of the self, achievable without changing the contents of experience at all. After 25 years away, he did a first-ever blindfolded, high-dose mushroom trip, describing intense synesthesia and moments where "heaven and hell," as he puts it, turned on whether he could let go of self-control, a skill he credits to mindfulness training.

    Integration is the real goal

    Harris closes on the aim he thinks matters most: wisdom portable into ordinary life, like giving a child undistracted attention, rather than living for periodic highs. "This cup is just as formless and as mysterious," he says, framing integration, not the peak experience, as the real point.

    Key takeaways

    • Harris frames psychedelics as a doorway into taking first-person experience seriously, not a practice to repeat indefinitely.
    • MDMA, an amphetamine-derived entactogen, is pharmacologically distinct from classic psychedelics like LSD and psilocybin.
    • He excludes anyone with a personal or family history suggestive of schizophrenia or bipolar disorder, matching clinical trial criteria.
    • With adequate dose and set and setting, he says these experiences almost always produce a significant effect, though bad trips remain possible.
    • He warns against chasing repeated peak experiences, since altered states are always temporary.
    • After 25 years away, he completed a first blindfolded, high-dose mushroom trip using mindfulness training to navigate its intensity.
    • His central claim: a psychedelic experience's value lies in how much of its insight carries into ordinary consciousness afterward, not the experience itself.

    More videos

    Keep watching